We need to bring R0 &lt; 1 to treat cancer too

Srikrishna, Devabhaktuni; Sachsenmeier, Kris F.

doi:10.1186/s13073-021-00940-9

Cited by 10 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The activation of T cells’ ability to destroy tumors is heavily influenced by the checkpoint inhibition resulting from the interaction between PD-1/PD-L1 and CTLA-4 in solid tumors. There is an active clinical study employing LNP as a carrier for therapeutic mRNA, exploring this specific mechanism [ 141 ]. The SNALP technology developed by Tekmira Pharmaceuticals, Inc. is considered one of the predominant lipid-based methods extensively employed for delivering nucleic acids systemically in various clinical trials.…”

Section: Lnps In Development/clinical Trial Pipeline In Industrymentioning

confidence: 99%

Chemistry and Art of Developing Lipid Nanoparticles for Biologics Delivery: Focus on Development and Scale-Up

John,

Monpara,

Swaminathan

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Lipid nanoparticles (LNPs) have gained prominence as primary carriers for delivering a diverse array of therapeutic agents. Biological products have achieved a solid presence in clinical settings, and the anticipation of creating novel variants is increasing. These products predominantly encompass therapeutic proteins, nucleic acids and messenger RNA. The advancement of efficient LNP-based delivery systems for biologics that can overcome their limitations remains a highly favorable formulation strategy. Moreover, given their small size, biocompatibility, and biodegradation, LNPs can proficiently transport therapeutic moiety into the cells without significant toxicity and adverse reactions. This is especially crucial for the existing and upcoming biopharmaceuticals since large molecules as a group present several challenges that can be overcome by LNPs. This review describes the LNP technology for the delivery of biologics and summarizes the developments in the chemistry, manufacturing, and characterization of lipids used in the development of LNPs for biologics. Finally, we present a perspective on the potential opportunities and the current challenges pertaining to LNP technology.

show abstract

Section: Lnps In Development/clinical Trial Pipeline In Industrymentioning

confidence: 99%

Chemistry and Art of Developing Lipid Nanoparticles for Biologics Delivery: Focus on Development and Scale-Up

John,

Monpara,

Swaminathan

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Each of the malignant tumors exhibit numerous, but unique, sets of somatically mutated proteins, and such neoantigens can serve as targets for the development of individualized therapeutic vaccines, also known as personalized cancer vaccines (PCV) [ 155 ]. In other words, PCV s rely on the specific neoantigens derived from the patient’s tumor tissue itself to induce the ASIR against the tumor cells [ 156 ]. Powered by the advent of next-generation genomic sequencing technologies and computational algorithms, it is now possible to efficiently map the individual cancer’s mutanome (tumor-specific repertoire of immunogenic antigens), which ultimately aids in the selection of the most suitable target neoantigen for preparing the PCV [ 19 , 155 ].…”

Section: Approaches To and Apparatus Of Therapeutic Vaccination In Hnsccmentioning

confidence: 99%

Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma—A Review

2023

View full text Add to dashboard Cite

Therapeutic vaccination is one of the most effective immunotherapeutic approaches, second only to immune checkpoint inhibitors (ICIs), which have already been approved for clinical use. Head and neck squamous cell carcinomas (HNSCCs) are heterogenous epithelial tumors of the upper aerodigestive tract, and a significant proportion of these tumors tend to exhibit unfavorable therapeutic responses to the existing treatment options. Comprehending the immunopathology of these tumors and choosing an appropriate immunotherapeutic maneuver seems to be a promising avenue for solving this problem. The current review provides a detailed overview of the strategies, targets, and candidates for therapeutic vaccination in HNSCC. The classical principle of inducing a potent, antigen-specific, cell-mediated cytotoxicity targeting a specific tumor antigen seems to be the most effective mechanism of therapeutic vaccination, particularly against the human papilloma virus positive subset of HNSCC. However, approaches such as countering the immunosuppressive tumor microenvironment of HNSCC and immune co-stimulatory mechanisms have also been explored recently, with encouraging results.

show abstract